All In Biotech

NDA 020571 · Pfizer INC

Camptosar

Irinotecan Hydrochloride · Injection

NovelAccelerated approvalPriority review

Last checked: Nov 19, 2026Latest source record: Apr 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jun 14, 1996

Approved uses

4

Original approval plus efficacy supplements

Registered trials

2,083

325 Phase 3, 315 recruiting

FAERS reports

11,125

10,272 serious, 2,058 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DIARRHEA and MYELOSUPPRESSION • Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt CAMPTOSAR and reduce subsequent doses if severe diarrhea occurs [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . • Severe myelosuppression may occur [see Warnings and Precautions (5.2) ] . WARNING: DIARRHEA and MYELOSUPPRESSION See full prescribing information for complete boxed warning . • Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or...

What it is approved for

From the label in effect May 12, 2026.

• CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. • CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )

Mechanism: Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • CAMPTOSAR · IRINOTECAN HYDROCHLORIDE 300MG/15ML (20MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • CAMPTOSAR · IRINOTECAN HYDROCHLORIDE 40MG/2ML (20MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • CAMPTOSAR · IRINOTECAN HYDROCHLORIDE 100MG/5ML (20MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Irinotecan" as an intervention, any sponsor and status, largest first.

All 2,083 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,417
  • off label use884
  • nausea810
  • vomiting713
  • myelosuppression697
  • death681
  • disease progression575
  • febrile neutropenia575
  • neutropenia545
  • fatigue487
  • pyrexia443
  • neuropathy peripheral432

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004391
2005171
2006151
2007171
2008271
2009309
2010411
2011395
2012576
2013356
2014239
2015444
2016332
2017344
2018425
2019474
2020544
2021544
2022856
2023858
20241,044
20251,106
2026713

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Camptosar* (Irinotecan HCL*) · HCPCS J9206

2024 spending

$1.6M

Beneficiaries

6,928

46,104 claims

Per beneficiary

$237

2024 ASP limit $2.67 per unit

View as table
YearSpending
2020$1,970,761
2021$1,725,327
2022$1,632,554
2023$1,542,097
2024$1,645,199

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,762 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.